Вакцинация в ревматологии: настоящее и будущее
Аннотация
В ревматологии значимость коморбидных инфекций за последнее время существенно увеличилась, особенно в связи с внедрением в клиническую практику генно-инженерных биологических препаратов. Одним из путей решения указанной проблемы является изучение и активное применение различных вакцин. В настоящем обзоре рассмотрены вопросы, касающиеся применения вакцин против гриппа, инфекций, обусловленных пневмококками, вирусами герпеса, папилломы человека и гепатита В у ревматологических больных. Обсуждается безопасность и иммуногенность вакцинации, связанной с предупреждением инфекций дыхательных путей как наиболее частой причины неблагоприятного исхода при ревматических заболеваниях. Обозначены основные направления будущих исследований по рассматриваемой проблеме.
Ключевые слова
ревматические заболевания,
коморбидные инфекции,
грипп,
пневмония,
хронические вирусные инфекции,
вакцинация
Об авторах
Б. С. Белов
НИИ ревматологии им. В. А. Насоновой
Россия
Россия
Д. В. Буханова
НИИ ревматологии им. В. А. Насоновой
Россия
Россия
Г. М. Тарасова
НИИ ревматологии им. В. А. Насоновой
Россия
Россия
Список литературы
1. WolfeF, Mitchell D.M., Sibley J.T. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994; 37 (4): 481-494.
2. Edwards C.J., Lian T.Y., Badsha H., Teh C.L., Arden N., Chng H.H. Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus. 2003; 12(9): 672-676.
3. Tyndall A.J., Bannert B., Vonk M., Airò P., Cozzi F., Carreira P.E. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010; 69 (10): 1809-1815.
4. Решетняк Т.М. Антифосфолипидныйсиндром: клиника, диагностика и вопросы патогенеза: Автореф. дисс.. докт. мед. наук. М.: 1999; 57.
5. Asherson R.A., Shoenfeld Y. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome-molecular mimicry? J Rheumatol 2000; 27 (1): 12-14.
6. Perry L.M., Winthrop K.L., Curtis J.R. Vaccinations for rheumatoid arthritis. Curr Rheumatol Rep 2014; 16 (8): 431.
7. Friedman M. A., Winthrop K. Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol. 2016; 28 (3): 330-336.
8. Friedman M.A., Winthrop K.L. Vaccines and Disease-Modifying Antirheumatic Drugs: Practical Implications for the Rheumatologist. Rheum Dis Clin North Am. 2017; 43(1): 1-13.
9. van Assen S., Agmon-Levin N., Elkayam O., Cervera R., Doran M.F., Dougados M. et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011; 70 (3): 414-422.
10. Singh J.A., Saag K.G., Bridges S.L. Jr, Akl E.A., Bannuru R.R., Sullivan M.C. et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016; 68 (1): 1-26.
11. Rubin L.G., Levin M.J., Ljungman P., Davies E.G., Avery R., Tomblyn M. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58 (3): e44-100.
12. Dougados M., Soubrier M., Antunez A., Balint P., Balsa A., Buch M.H. et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014; 73 (1): 62-68.
13. Lawson E.F., Trupin L., von Scheven E., Yelin E.H., Yazdany J. Reasons for failure to obtain influenza and pneumococcal vaccines among immunosuppressed individuals with systemic lupus erythematosus. Arthritis Rheum 2013; 65: 10: Suppl: 362.
14. Krasselt M., Baerwald C., Seifert O. Insufficient vaccination rates in patients with systemic lupus erythematosus in a German outpatient clinic. Z Rheumatol 2017 Dec 13. doi: 10.1007/s00393-017-0410-5.
15. Kapetanovic M.C. Do encourage your scleroderma patients at risk to get influenza vaccine. Rheumatology. 2017 Oct 25. doi: 10.1093/rheumatol-ogy/kex380
16. Brocq O., Acquacalda E., Berthier F., Albert C., Bolla G., Millasseau E. et al. Influenza and pneumococcal vaccine coverage in 584 patients taking biological therapy for chronic inflammatory joint: A retrospective study. Joint Bone Spine 2016; 83 (2): 155-159.
17. Williams G.W., Steinberg A.D., Reinertsen J.L., Klassen L.W., Decker J.L., Dolin R. Influenza immunization in systemic lupus erythematosus. A double-blind trial Ann Intern Med 1978; 88 (6): 729-734.
18. Brodman R., Gilfillan R., Glass D., Schur P.H. Influenza vaccine response in systemic lupus erythematosus. Ann Intern Med 1978; 88 (6): 735-740.
19. Louie J.S, Nies K.M., Shoji K.T., Fraback R.C., Abrass C., Border W. et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 1978; 88 (6): 790-792.
20. Ristow S.C., Douglas R.G. Jr., Condemi J.J. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med 1978; 88 (6): 786-789.
21. Herron A., DettleffG, Hixon B., Brandwin L., Ortbals D., Hornick R. et al. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA 1979; 242 (1): 53-56.
22. Holvast A., van Assen S., de Haan A., Huckriede A., Benne C.A., Westra J. et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum 2009; 60 (8): 2438-2447.
23. Holvast A., van Assen S., de Haan A., Huckriede A., Benne C.A., Westra J. et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology 2009; 48 (10): 1294-1299.
24. Concept Paper on the Revision of the CPMP/ BWP Note for Guidance on Harmonization of Requirements for Influenza Vaccines (CPMP/ BWP/214/96)./London, 31 May, 2001/CPMP/EWP/1045/01.
25. Kostianovsky A., Charles P., Alves J.F., Goulet M., Pagnoux C., Le Guern V. et al. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. Clin Exp Rheumatol 2012; 30: 1: Suppl 70: S83-89.
26. Blumentals W.A., Arreglado A., Napalkov P., Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study.BMC Musculoskelet Disord 2012 ;13: 158.
27. Miraglia J.L., Abdala E., Hoff P.M., Luiz A.M., Oliveira D.S., Saad C.G. et al. Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. PLoS One 2011; 6 (11): e27214.
28. Franga I.L., Ribeiro A.C., Aikawa N.E., Saad C.G., Moraes J.C., Goldstein-Schainberg C. et al. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients.Rheumatology 2012; 51 (11): 2091-2098.
29. Kobie J.J., Zheng B., Bryk P., Barnes M., Ritchlin C.T., Tabechian D.A. et al. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.Arthritis Res Ther 2011; 13 (6): R209.
30. Elkayam O., Bashkin A., Mandelboim M., Litinsky I., Comaheshter D., Levartovsky D. et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010; 39 (6): 442-447.
31. Kaine J.L., Kivitz A.J., Birbara C., Luo A.Y. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007; 34 (2): 272-279.
32. Kivitz A.J., Schechtman J., Texter M., Fichtner A., de Longueville M., Chartash E.K. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial. J Rheumatol 2014; 41 (4): 648-657.
33. Park J.K., Lee M.A., Lee E.Y., Song Y.W., Choi Y., Winthrop K.L. et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2017; 76 (9): 1559-1565.
34. Tsuru T., Terao K., Murakami M., Matsutani T., Suzaki M., Amamoto T., et al. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol 2014; 24 (3): 511-516.
35. Ribeiro A.C., Laurindo I.M., Guedes L.K., Saad C.G., Moraes J.C., Silva C.A. et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res 2013; 65 (3): 476-480.
36. Genovese M.C., Bingham C.O., Cohen S., Calabrese L., Curtis J.R., Block A. et al. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving subcutaneous abatacept. Arthritis Rheum 2013; 65: 10: Suppl: 198.
37. van Assen S., Holvast A., Benne C.A., Posthumus M.D., van Leeuwen M.A., Voskuyl A.E. et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010; 62 (1): 75-81.
38. Eisenberg R.A., Jawad A.F., Boyer J., Maurer K., McDonald K., Prak E.T. et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 2013; 33 (2): 388-396.
39. Hua C., Barnetche T., Combe B., Morel J. Effect of methotrexate, anti-tumor necrosis factor а, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 2014; 66 (7): 1016-1026.
40. Kapetanovic M.C., Kristensen L.E., Saxne T., Aktas T., M?rner A., Geborek P. et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther 2014; 16 (1): R2.
41. Shinjo S.K., de Moraes J.C., Levy-Neto M., Aikawa N.E., de Medeiros Ribeiro A.C., Schahin Saad C.G. et al. Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and no harmful effect in disease. Vaccine 2012; 31 (1): 202-206.
42. Setti M., Fenoglio D., Ansaldi F., Filaci G., Bacilieri S., Sticchi L. et al. Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 2009; 27 (25-26): 3367-3372.
43. Sampaio-Barros P.D., Andrade D.C.O., Seguro L.C.P., Pasoto S.G., Viana V.S.T., Ribeiro A.C.M. et al. Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis. Rheumatology 2017 Sep 8. doi: 10.1093/rheumatology/kex330.
44. Wotton C.J., Goldacre M.J. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health 2012; 66 (12): 1177-1181.
45. Koivuniemi R., Leirisalo-Repo M., Suomalainen R., Piirainen H., Paimela L. Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand J Rheumatol 2006; 35: 273-276.
46. Nossent J., Cices N., Kiss E. Marchesoni A., Nassonova V., Mosca M. et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Lupus 2007; 16: 309-317.
47. Narata R., Wangkaew S., Kasitanon N., Louthrenoo W. Community-acquired pneumonia in Thai patients with systemic lupus erythematosus. Southeast Asian J Trop Med Public Health 2007; 38: 3: 528-536.
48. Mercado U. Why have rheumatologists been reluctant to vaccinate patients with systemic lupus erythematosus? J Rheumatol 2006; 33 (8): 1469-1471.
49. Kapetanovic M.C., Saxne T., Sj?holm A., Truedsson L., J?nsson G., Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology 2006; 45 (1): 106-111.
50. Bingham C.O. 3rd, Rizzo W., Kivitz A., Hassanali A., Upmanyu R., Klearman M. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA). Ann Rheum Dis 2015; 74 (5): 818-822.
51. Bingham C.O. 3rd, Looney R.J., Deodhar A., Halsey N., Greenwald M., Codding C. et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010; 62 (1): 64-74.
52. Crnkic Kapetanovic M., Saxne T., J?nsson G., Truedsson L., Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.Arthritis Res Ther 2013; 15 (5): R171.
53. Pham T., Claudepierre P., Constantin A., Fautrel B., Gossec L., Gottenberg J.E. et al. Abatacept therapy and safety management. Joint Bone Spine 2009; 76: Suppl 1: S3-S55.
54. Наумцева М.С., Белов Б.С., Александрова Е.Н.,.Тарасова Г.М., Новиков A.A., Каратеев Д.Е. и др. Иммуногенность и безопасность 23-валентной полисахаридной пневмококковой вакцины у больных ревматоидным артритом: результаты двухлетнего наблюдения. Научно-практическая ревматология 2016; 54 (6): 674-680.
55. Mercado U., Acosta H., Diaz-Molina R. Antibody response to pneumococcal polysaccharide vaccine in systemic sclerosis.J Rheumatol 2009; 36 (7): 1549-1550.
56. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWRMorbMortalWklyRep 2012; 61: 816-819.
57. Вакцинопрофилактика пневмококковой инфекции. Федеральные клинические рекомендации. М.: 2015; 24.
58. Kapetanovich M., Nagel J., Nordstr?m I., Saxne T., Geborek P., Rudin A. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine 2017; 35 (6): 903-908.
59. Salinas G.F., De Rycke L., Barendregt B., Paramarta J.E., Hreggvidstdottir H., Cantaert T. et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis 2013; 72: 1037-1043.
60. Migita K., Akeda Y., Akazawa M., Tohma S., Hirano F., Ideguchi H. et al. Opsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab Plus Methotrexate. Medicine Baltimore 2015; 94 (52): e21843.
61. Grabar S., Groh M., Bahuaud M., Le Guern V., Costedoat-Chalumeau N., Mathian A. et al. Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study. Vaccine 2017; 35 (37): 4877-4885.
62. Curtis J.R., Yang S., Chen L.,Winthrop K., Xie F., Baddley J.W., et al. Herpes zoster infection across auto-immune and inflammatory diseases: implications for vaccination. Ann Rheum Dis 2014; 73: Suppl 2: 452.
63. Che H., Lukas C., Morel J., Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine 2014; 81 (4): 379-380.
64. Winthrop K.L., Curtis J.R., Lindsey S., Tanaka Y., Yamaoka K., Valdez H. et al. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Arthritis Rheumatol 2017; 69 (10): 1960-1968.
65. Guthridge J.M., Cogman A., Merrill J.T., Macwana S., Bean K.M., Powe T. et al. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol 2013; 40 (11): 1875-1880.
66. Zhang J., Xie F., Delzell E., Chen L., Winthrop K.L., Lewis J.D. et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308 (1): 43-49.
67. Yun H., Xie F., Baddley J.W., Winthrop K., Saag K.G., Curtis J.R. Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases. J Rheumatol 2017; 44 (7): 1083-1087.
68. Ferreira I., Isenberg D. Vaccines and biologics. Ann Rheum Dis. 2014 Aug; 73 (8): 1446-1454.
69. Chakravarty E.F. Incidence and Prevention of Herpes Zoster Reactivation in Patients with Autoimmune Diseases. Rheum Dis Clin North Am 2017; 43 (1): 111-121.
70. Klumb E.M., Pinto A.C., Jesus G.R., Araujo M. Jr., Jascone L., Gayer C.R. et al. Are women with lupus at higher risk of HPV infection? Lupus 2010; 19 (13): 1485-1491.
71. Lyrio L.D., Grassi M.F., Santana I.U., Olavarria V.G., Gomes Ado N. et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int. 2013; 33 (2): 335-340.
72. Mok C.C., Ho L.Y., Fong L.S., To C.H. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2013; 72 (5): 659-664.
73. Dhar J.P, Essenmacher L., Dhar R., Magee A., Ager J., Sokol R.J. The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Vaccine 2017; 35 (20): 2642-2646.
74. Moraes-Fontes M.F., Antunes A.M., Gruner H., Riso N. Vaccination of Adult Patients with Systemic Lupus Erythematosus in Portugal. Int J Rheumatol 2016; 2016: 2845617.
75. Mathian A., Arnaud L., Adoue D. Agard C., Bader-Meunier B., Baudouin V. et al. Prevention of infections in adults and adolescents with systemic lupus erythematosus: Guidelines for the clinical practice based on the literature and expert opinion. Rev Med Interne. 2016; 37 (5): 307-320.
76. Caporali R., Bobbio-Pallavicini F., Atzeni F., Sakellariou G., Caprioli M., Montecucco C. et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res 2010; 62 (6): 749-754.
77. Tan.J, Zhou J., Zhao P., Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol 2012; 31 (8): 1169-1175.
78. Elkayam O., Yaron M., Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002; 61 (7): 623-625.
79. Alvarez M.M., Fernandes C.G., Exposito A.G. Antibody response to the standard hepatitis B vaccination in patients with rheumatoid arthritis an ankylosing spondilitis treated with infliximab. Arthritis Rheum 2011; 63 (10): Suppl 1: 515.
Рецензия
Для цитирования:
Белов Б.С., Буханова Д.В., Тарасова Г.М. Вакцинация в ревматологии: настоящее и будущее. Антибиотики и Химиотерапия. 2018;63(1-2):56-68.
For citation:
Belov B.S., Bukhanova D.V., Tarasova G.M. Vaccination In Rheumatology: Present And Future. Antibiot Khimioter = Antibiotics and Chemotherapy. 2018;63(1-2):56-68. (In Russ.)
Просмотров:
336
Послать статью по эл. почте 